window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 22, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

molecular glue degraders

  • Biotech,Clinical Trials,Drug discovery,Funding,Oncology,Partnerships & Funding,Pharmaceuticals and therapeutics,Research & Development,Technology and platforms

    Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline

    Neomorph has closed a $100 million Series B financing to [...]

    April 18, 2026
  • Biotech,Drug discovery,Healthcare leadership,Movers & Shakers,Research & Development,Startups and innovations,Technology and platforms

    Proxygen appoints Chiara Conti as chief scientific officer to support move into clinical-stage development

    Proxygen has appointed Chiara Conti as chief scientific officer, as [...]

    April 2, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Emalex secures US patent for ecopipam orally disintegrating tablet in Tourette syndrome
    Categories: Central Nervous System, Clinical Development, Drug Delivery & Formulation, Drug Development, Neurosciences, Patient Centricity
  • Currax highlights peer-reviewed review supporting combination approaches in obesity treatment
    Categories: Obesity, Pharmaceuticals and therapeutics, Research & Development
  • MaaT Pharma publishes real-world CHRONOS data in third-line acute GvHD
    Categories: Clinical Development, Clinical studies, Hematology, Regulatory Affairs, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top